Coherus Oncology (CHRS) at 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Corporate Strategy and Transformation

• Transitioned from biosimilars to a fully integrated, commercial-stage immuno-oncology company in 2024, focusing on innovative oncology assets and streamlining operations.

• Completed or announced three major transactions, raising $800 million in non-dilutive capital and divesting legacy biosimilar assets, including UDENYCA, to focus on immuno-oncology.

• Divestiture of biosimilar assets, including UDENYCA, is expected to close in Q1 2025, raising up to $483 million in upfront cash and enabling full repayment of $230 million in convertible debt and $49 million in royalty obligations.

• Maintains a strong balance sheet with $125 million in cash at year-end 2024, with post-divestiture cash runway exceeding two years and further financial strengthening through ex-U.S. partnerships.

• Proceeds from the UDENYCA sale will be used to strengthen the balance sheet and fund the oncology pipeline.

Pipeline and Clinical Development

• LOQTORZI (toripalimab/toripalimab-tpzi) is the foundational PD-1 asset, uniquely differentiated by its binding epitope and strong T cell activation, and is the only FDA-approved therapy for nasopharyngeal cancer in all lines.

• Casdozokitug (IL-27 inhibitor/antagonist) demonstrated immune activation, durable responses, and acceptable safety in lung and liver cancer, with ongoing and planned studies in HCC and NSCLC.

• CHS-114 (CCR8 antibody) selectively depletes tumor-resident Tregs, showing safety, proof of concept, and disease control in early trials, with expansion into head and neck and gastric cancers.

• Multiple data readouts and pivotal trial initiations are scheduled for 2025–2026, including Phase 2 and Phase 1b studies across key indications.

• The pipeline is designed to improve response rates and durability in immuno-oncology without significant added toxicity.

Commercial Opportunity and Market Outlook

• LOQTORZI is the only FDA-approved therapy for nasopharyngeal cancer, now positioned as the standard of care in NCCN guidelines, with a $150–$200 million market opportunity and about 2,000 eligible patients annually.

• Rapid revenue ramp anticipated, with LOQTORZI sales showing consecutive quarter-over-quarter growth above 20% since launch and peak sales expected in about four years.

• Commercial strategy leverages combination therapies, aiming to expand into treatment deserts such as colorectal, pancreatic, and ovarian cancers.

• Total addressable market for the current pipeline is estimated at $15 billion, with synergistic sales of LOQTORZI and pipeline agents.

• Updated promotional strategies are in place to accelerate LOQTORZI's ramp to peak sales following guideline revisions.